Answers are grounded in this paper and cite their sources.
This review summarizes the current knowledge on the pathogenesis and epidemiologic characteristics of anti-ERBB2 ADC-related lung toxicity, proposing strategies for its diagnosis and treatment. Earlier diagnosis and more adequate treatment of ADC-induced ILD may improve the therapeutic index of this important class of anticancer agents, allowing for a safe expansion of anti-ERBB2 ADCs across tumor types.
No takes yet. Share an insight, caveat, or question.
Tarantino et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: